<?xml version='1.0' encoding='utf-8'?>
<document id="32002956"><sentence text="Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7."><entity charOffset="45-53" id="DDI-PubMed.32002956.s1.e0" text="acridine" /></sentence><sentence text="The compound 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), the promising antitumor agent developed in our laboratory was determined to undergo phase I metabolic pathways"><entity charOffset="13-62" id="DDI-PubMed.32002956.s2.e0" text="9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine" /></sentence><sentence text=" The present studies aimed to know its biotransformation with phase II enzymes - UDP-glucuronosyltransferases (UGTs) and its potential to be engaged in drug-drug interactions arising from the modulation of UGT activity" /><sentence text="" /><sentence text="UGT-mediated transformations with rat liver (RLM), human liver (HLM), and human intestine (HIM) microsomes and with 10 recombinant human isoenzymes were investigated" /><sentence text=" Studies on the ability of C-1748 to inhibit UGT were performed with HLM, HT29 colorectal cancer cell homogenate and the selected recombinant UGT isoenzymes" /><sentence text=" The reactions were monitored using HPLC-UV/Vis method and the C-1748 metabolite structure was determined with ESI-TOF-MS/MS analysis" /><sentence text="" /><sentence text="Pseudo-molecular ion (m/z 474" /><sentence text="1554) and the experiment with β-glucuronidase indicated that O-glucuronide of C-1748 was formed in the presence of microsomal fractions"><entity charOffset="61-74" id="DDI-PubMed.32002956.s10.e0" text="O-glucuronide" /></sentence><sentence text=" This reaction was selectively catalyzed by UGT2B7 and 2B17" /><sentence text=" High inhibitory effect of C-1748 was shown towards isoenzyme UGT1A9 (IC50 = 39" /><sentence text="7 μM) and significant but low inhibitory potential was expressed in HT29 cell homogenate (IC50 = 84" /><sentence text="5 μM)" /><sentence text=" The mixed-type inhibition mechanism (Ki = 17" /><sentence text="0 μM; Ki '= 81" /><sentence text="0 μM), induced by C-1748 was observed for recombinant UGT1A9 glucuronidation, whereas HT29 cell homogenate resulted in noncompetitive inhibition (Ki = 94" /><sentence text="6 μM)" /><sentence text="" /><sentence text="The observed UGT-mediated metabolism of C-1748 and its ability to inhibit UGT activity should be considered as the potency for drug resistance and drug-drug interactions in the prospective multidrug therapy" /><sentence text="" /></document>